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Ablation, renal, hypertension (abst) 260












Acetohyroxamic acid, stones (abst)
Acetylated alkyl phosphoglycerides, PAF
Acetylcholine
decreased endothelium-dependent relaxations (abst) ... 256
Acid
cyclosporine stimulates secretion (abst) 368
regulation of renal secretion, distal nephron segments. 1099
sulfated bile, inhibition of Na-H antiport (abst) 1257
Acid fast bacillus in dialysis (abst) 230
Acid-base
balance, urea formation (abst) 367
disturbance, bicarbonate conductance to HCO3- (abst) . 375
disturbance, edema (abst) 197
metabolism after ischemia 989
respiratory during HD (abst) 220
status in HD (abst) 227
systemic effects, regulation of glutamine metabolism in
dog 68
Acidemia
systemic, chronic mineral acid feeding and pH 667
Acidification
cellular, activates Na-H exchange and Na-K pump
(abst) 397
clathrin-coated vesicle, by vanadate (abst) 364
metabolic alkalemia, IMCD (abst) 363
ureteral obstruction 1167
urinary, PTH (abst) 363
Acidosis
acid-base metabolism after ischemia 989
anion gap, hemodialysis (abst) 197
extracellular on active transport processes (abst) 409
Fanconi syndrome (abst) 296
lactic 752
nephrectomy, effect on glutamine homeostasis (abst)... 365
newborns, treatment of ARF with CAVH 908
potassium depletion (abst) 363
potassium depletion during chronic metabolic (abst) . . . 374
respiratory inhibits cAMP HCO3 secretion (abst) 362
respiratory, stimulates ammoniagenesis (abst) 355
substrate oxidation, ammoniagenic adaptation (abst) . . . 356
systemic, proton-ATPase in tubules (abst) 368
Acids
heterpolyuronic, non-aluminum S- 120
polyunsaturated 279
Acivicin effect on glutamine (abst) 359
Acquired renal cystic disease
magnetic resonance imaging, ultrasound in (abst) 196
Actin-regulatory proteins
are in apical cytoplasm of kidney collecting duct (abst). 413
Acute oliguric renal failure
monoclonal antibodies in diagnosis of renal disease.... 142
Acute postinfections GN (abst) 1250
Acute renal failure
changing patterns and outcome of (abst) 176
chronic uremia, mouse model (abst) 318
cisplatin (abst) 312
endotoxemic (abst) 306
endotoxin-mediated, theophylline (abst) 308
HR effect on cisplatin-induced (abst) 300
insulin (abst) 306
ischemia, hypothyroidism protects against free radical. 1162
ischemic, dipyridamole (abst) 305
laser Doppler velocimetry (abst) 297
mannitol in high risk patients (abst) 298
metabolic adaptations in renal disease 80
nephrotoxic in streptozotocin treated rats (abst) 301
nifedipine on carbohydrate metabolism (abst) 1257
norepinephrine-induced, vascular congestion 306
outcome prediction in (abst) 184
prostaglandins induced by captopril (abst) 338
proton magnetic resonance (abst) 302
reduced blood pressure (abst) 256
renal blood flow, prostaglandin in glycerol-induced
(abst) 342
reversal due to urinary tract infection (abst) 176
ribonuclease II iszyme activity (abst) 305
TXA2 in glycerol-induced (abst) 42
vascular aberrancies of (abst) 299
verapamil (abst) 312
Acute renal injury
gasoline injestion (abst) 304
Acute renal insufficiency
reversible due to diuretic, Maxzide (abst) 198
Acute tubular necrosis
autofluorescence (abst) 289
diabetes mellitus protects against (abst) 308
monoclonal antibodies in diagnosis 142
Adenine nucleotide degradation (abst) 296
Adenosine
inhibits chloride secretion in shark rectal gland (abst) . . 337
triphosphate levels ischemic insult (abst) 310
transport (abst) 332
Adenyl cyclase, PTH, H20 flow (abst) 170
Adenylate cyclase, vasopressin (abst) 424
Adrenal
corticosteroids, transport(abst) 407
steroids, permeability (abst) 417
unilateral rnedullary hyperfunction (abst) 245
Adrenalectomized
rabbit, K bicarbonate on Na-K-ATPase CCD (abst).... 395
Adrenalectomy, protein in uremic (abst) 309
Adrenoceptor
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posterior hypothalamic B-2 in SHR (abst) 249
Adult idiopathic nephrotic syndrome
membranoproliferative glomerulonephritis in (abst) .... 207
Adult-onset nephrotic syndrome 1250
Age
and PTH (abst) 175
donor influence on transplant(abst) 942
renal cortical brush border membrane enzyme activity
(abst) 360
AIDS
associated renal failure, national perspective (abst) . . . . 201
nephrotic syndrome (abst) 288
Albumin
homeostasis, dietary protein 572
homeostasis in nephrotics 572
hyperoncotic, natriuresis (abst) 392
Albumin, bovine serum, binding (abst) 265
Albuminuria
enalapril blocks (abst) 320
hyperlipimia (abst) 193
Aldosterone
changes in short-circuit current and conductance (abst). 408
induced glycoproteins in toad (abst) 351
induces Cl transport in CCT (abst) 1252
in vivo 208
mineralcorticoid (abst) 242
19-NOR potent (abst) 253
19-OH, 19-NOR (abst) 242
Alkali
nural regulation of excretion (abst) 365
therapy in CRF (abst) 323
Alkaline
growth of proximal tubular cells occurs (abst) 402
Alkalinization
canine renal proximal tubular cells, phorbol ester (abst) . . 372
Alkalosis
chloride corrects without volume expansion (abst) 364
chloride depletion, new dog model (abst) 364
volume expansion not correct acute chloride depletion
(abst) 365
Allergy, food, and idiopathic NS (abst) 776
Allograft
age of donor impact on survival (abst) 942
deposits of cyclosporine in (abst) 612
Alpha 2-adrenoceptors
dopamine receptors in diuresis (abst) 395
Alpha-ketoisocaproate, uremic (abst) 326
Alport's syndrome
epidermal basement membrane antigens (abst) 279
expression of Goodpasture antigen in 202
Alsosterone secretion, PTH (abst) 168
Aluminum
addition on parathyroid tissue incubation medium 924
and iron removal after DFO in CAPD, HD and HF
(abst) 171
Australia, and bone disease in S-65
binding protein in bovine duodenal extracts (abst) 154
bone biopsy and storage of (abst) 173
bone, longitudinal study 218
CaCO3 on K, Ca, and Mg balance in ESRD (abst) .... 219
carbon, microencapsulated, used for removal (abst).... 226
changes in bone histology after desferrioxamine treat-
ment S-l08
clearance of by hemodialysis, desferrioxamine S-l00
desferoxamine treatment of anemia in dialysis (abst)... 210
diagnosing bone disease S-96
dialysis encephalopathy S-53
effect on bone and cell localization S-37
effect on bone and cell localization S-37
elevated levels in CRF patients (abst) 176
enhanced gastrointestinal adsorption in uremic (abst).. 1260
erythropoiesis (abst) 610
experimental induced bone disease S-32
geochemistry S-3
hematopoiesis S-45
hemoperfusion in treatment of bone disease (abst) 214
in genesis of osteodystrophy 169
interactions with cofactors, enzymes and proteins . . . . S-12
intoxication of bone in renal failure S-70
metabolism S-8
Mg hydroxide, low Mg dialysate in CAPD (abst) 232
mineralization during matrix-induced bone develop-
ment 1038
non, phosphate-binding compound S-120
parathyroid glands function despite exposure (abst).... 170
phosphate binding gels balance adsorption, toxicity... 1131
plasma, toxicity S-91
PTH and vitamin D on intestinal and renal handling of
(abst) 173
PTH and vitamin D3 affect accumulation (abst) 213
PTH not prevent osteomalacia 168
related bone disease, clinical & laboratory features
(abst) 199
related osteodystrophy 169
removal during HD and CAPD, effect of DFO infusion
(abst) 190
removal in home dialysis 209
serum and spinal fluid levels in HD uremics (abst) 211
serum levels in dialysis patients (abst) 165
suppression of DNA synthesis by bone cells (abst) . . . . 157
toxicity resembles aplastic bone disease (abst) 164
toxicity, experimental renal failure (abst) 175
Amiloride
effect on bicarbonate (abst) 375
protects antiporter vs EEDQ (abst) 405
on transport (abst) 163
Na+ channel (abst) 1255
Amino acid
combined infustion of, and dopamine, renal hemody-
namics 870
low protein, keto acid diet, risk and benefit 995
mercury in basolateral cell membrane (abst) 416
Na transport, lipid events, adaptive response to (abst) . 413
renal hemodynamics during infustion of, and dopamine. 870





ammonium on NaIH antiporter, kinetic effects (abst)... 402
concentration in inner medulla (abst) 366
genic adaptation to substrate oxidation, acidosis (abst) . 356
inhibits tubule cell energy metabolism (abst) 352
K transport in turtle bladder (abst) 377
transport, transepithelial (abst) 366
tubular C3 deposit (abst) 293
Ammoniagenesis
acetazolamide (abst) 354
acute respiratory acidosis stimulates (abst) 355
AT-125 on renal (abst) 361
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gluconeogenesis, 13C NMR, 15N GC-MS (abst) 357
plasma glutamine concentration (abst) 351
regulaton of glutamine metabolism in dog kidney 68
renal cortical mitochondrial, PGE2 (abst) 355
vaiproate (abst) 350
Ampflex connector (abst) 237
Amphiuma
apical membrane conductance (abst) 398
Amphiuma collecting tubule (abst) 398
Amyloid
lambda 2 light chain (abst) 288
type, diagnosis (abst) 274
B2 microglobulin, carpal tunnel syndrome (abst) 213
Amyloidosis
incidence in population of 250,000 (abst) 777
in heroin abusers (abst) 187
Anabolism in hemodialysis (abst) 209
Analogs, adenosine on GFR (abst) 358
Anaphylactic reactions, dialyzers (abst) 212
Anaphylatoxin
cardiopulmonary effect of cuprophane-activated plasma.. 799
cobra venom factor(abst) 269
Anemia
in hemodialysis (abst) 214
chronic renal failure 641
Anencephalic neonate donor
transplantation of cadaver kidneys from (abst) 430
Aneurysm, glomerular (abst) 286
ANFT, metabolic/excretory coupling(abst) 360
Angiotensin
vasomotor response to reflex sympathetic activation
(abst) 610
Angiotensin converting enzyme
clipped kidney in hypertensive rats during prolonged
(abst) 246
experimental nephrotic syndrome (abst) 302
Angiotensin II
aldosterone secretion, protein phosphorylation (abst) .. 329
binding sites in segments of rat nephron (abst) 254
blood pressure, vascular reactivity (abst) 383
BP control in normotensive members of hypertensive
families 882
Ca kinetics 424
calcium, cyclooxygenase modulate renal function (abst).. 336
chronic salt loading, glomeruli (abst) 385
hypertrophy vs. hyperplasia (abst) 318
in nephrotoxic serum nephritis (abst) 293
PGE2 synthesis by pertussis toxin (abst) 344
role for water intake (abst) 1252
Antiotensin II
segmental vascular diameter response to (abst) 381
vasopressin, cause membrane depolarization (abst).... 341
22Na+ washout from VSMCs (abst) 338
Anion exchange, band 3 (abst) 376
Anionic sites
albumin excretion (abst) 294
phosphate (abst) 285
Anisotonic media regulation (abst) 419
Anoxia, adenine nucleotides (abst) 357
Anoxic cell death, Ca, nephron segment 1172
Anoxic renal PT, acidosis (abst) 299
Anti-diuretic hormone
cAMP, regulation of water permeability in bladder
(abst) 417
fluorescent markers study membrane retrieval in (abst). 416
Anti-glomerular basement membrane
antibody mediated disease, outcome (abst) 200
Anti-inflammatory drug
sulinas effect during hemorrhage 484
Anti-interleukin-2 receptor (abst) 280
Anti-thymocyte globulin, CyA (abst) 427
Antibiotic induced renal failure (abst) 177
Antibiotic schedule for CAPD (abst) 231
Antibodies
auto-anti-idiotypic in anti-GBM GN (abst) 290
heparan sulfate proteoglycans of GBM (abst) 283
monoclonal, to mononuclear cell markers 708
MRL nephritogenic, share dominant ideotype (abst) ... 285
to laminin in preeclarnpsia 1050
viral glycoprotein, endocytosis (abst) 420
immune complex (abst) 271
monoclonal Enkephalin degrading enzyme (abst) 271
monoclonal in diagnosis 142
Antibody
anti-GBM in auto-immune nephritis 266
antigen, in heymann nephritis (abst) 608
antigliadin in IgA glomerulonephritis (abst) 776
characterization of monoclonal, Tamm-Horsfall protein .. 971
monoclonal anti-rat-thymocyte, glomerulonephritis
(abst) 945
reaginic ETO response (abst) 266
to acidic protein MAUP in urine (abst) 264
urinary calcium oxalate crystal growth inhibitor 829
Antibody binding
tubular C3 deposition by ammonia (abst) 293
Antidiuresis
increased urinary excretion of PGE2 1110
Antidiuretic hormone
mechanism of in natriuresis (abst) 422
nucleotide regulatory protein mediates (abst) 423
type B syndrome of inappropriate (abst) 421
Antigen
antibody, glomerular capillary wall charge interactions . 649
exogenous cationized, Heymann Nephritis (abst) 264
immunocytochemical localization of renin and
kallikrein 965
nucleic acid, membranous lupus autoantibodies (abst). . 288
of antiglomerular basement membrane antibody (abst). 1248
Antigen-antibody systems
Heymann Nephritis (abst) 263
7OKD, HN (abst) 291
Antigens
HLA-DR, DP, DQ, on human tissue (abst) 1261
immunodissection and culture of CCT (abst) 424
microheterogeneity, nephritis, 2D-SDS immunoblotting
(abst) 1249
MHC minimal change glomerulonephritis, focal sclero-
sis (abst) 286
multiple, MRL antibody (abst) 285
Antihypertensive
drug, guanabenz 1203
hepatic dysfunction in transplant (abst) 438
treatment, effects in one-clip, two kidney hypertension.. 1011
therapy, decrease of NAG after (abst) 258
Antiport
Na activates Na-H activity at internal locus (abst) 396
Na-H activity in LLCPK1-CL4 cells (abst) 403
Antiporter
kinetics of Na-H, pH in MDCK cells (abst) 376
Na+/H+, amiloride protects vs inactivation (abst) 405
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Na+/H+, CL-/HCO3-(OH-) transport NaC1 (abst) 390
Na/H and PTH (abst) 372
with exchanger, BBM (abst) 367
APD, hyperparathyroidism (abst) 1262
Apical membrane vesicles
LLC-PK1, new type of exchange system of Na+/H+
(abst) 373
Aplastic bone disease, dialysis S-74
Arachidonate acid epoxygenase (abst) 356
Arachidonic acid
metabolites, prostaglandins in the kidney 108
Arginine infusion
on renal plasma flow and GFR in humans (abst) 190
Arginine vasopressin
action (abst) 328
action cellular calcium uptake modulates in CCT (abst). 415
analysis 178
mechanism in MAL (abst) 418
pertussis toxin, adenylate cyclase activity (abst) 426
modulation of hormonal action by 863
receptor characteristics of human platelet (abst) 412
Arterial
dopamine-2 receptor in canine kidney (abst) 385
Arterial line, blood in HD (abst) 943
Arteries, renal
endothelium-deptndent relaxation (abst) 251
Arterioles
isolated renal afferent, PGE2 (abst) 385
glomerular, APII (abst) 333
Arteriovenous shunting (abst) 195
Arthritis
rheumatoid, CyA, Aza side effects in treatment of.... 1180
Aspirin, GFR (abst) 323
Assay
D valine medium (abst) 353
new chromogenic endotoxin (abst) 207
PTH in CAPD (abst) 239
AT-125, ammoniagenesis (abst) 361
Atenolol in hypertensives (abst) 205
Atomic absorption spectroscopy
electrothermal determination of aluminum S-28
Atomic emission spectrometry, aluminum S-24
ATPase
acetate intolerance during HD (abst) 223
activity in proximal tubule brush border membrane
(abst) 368
clathrin-coated vesicle proton translocating (abst) 378
depletion 302
distribution and function along the nephron 21
luminal active transport processes in cortical cells
(abst) 611
mechanism, produced by exogenous nucleotides (abst). 356
monoclonal antibody to bovine medulla H+ 369
mutant clathrin-coated vesicle proton translocating
(abst) 377
Na-K, in streptozotocin-induced diabetes mellitus
(abst) 410
recovery, postischemic (abst) 299, 315
sodium pump in salt gland, gut tube of brine shrimp
(abst) 394
sodium transport, oxygen consumption and 3
to sodium transport (abst) 359
Atrial extracts, properties, rat (abst) 248
Atrial natriuretic factor
acute hormonal and hemodynamic effects of in man
(abst) 1253
aorto-caval fistula (abst) 389
causes glomerular hyperfiltration, cAMP, TGF (abst) . . 384
changes in dietary protein (abst) 384
chronic sodium homeostasis 1004
furosemide induced natriuresis (abst) 398
in salt-sensitive DAHL rats (abst) 334
in vascular smooth muscle cells (abst) 258
increase excretion, GFR (abst) 332
induce a natriuresis, GFR (abst) 402
intrarenal effects of (abst) 408
medullary solute gradients (abst) 414
ouabain factor, high Na diet (abst) 404
plasma and urine levels following ANF infusion (abst) . 409
plasma, hypervolemia (abst) 395
relationship between, and renal kallikrein (abst) 1254
respiration (abst) 340
Atrial natriuretic peptide
acute hemodynamic effect of (abst) 383
angiotensin II and hyperoncotic albumin (abst) 340
artificial heart transplant (abst) 192
atrial resection limits in sodium excretion (abst) 407
blood levels, cardiovascular, endocrine, excretory
(abst) 348
diabetes insipidus, natriuretic effect (abst) 390
dopamine (abst) 336
during mineralocorticoid escape (abst) 329
effect of on kidney and juxtamedullary nephron (abst). . 405
effects of on kidney function in man (abst) 388
hydraulic pressures, natriuresis (abst) 382
in plasma of children with ESRD and volume expan-
sion (abst) 1254
increase plasma insulin (abst) 348
inhibitory effect of on cAMP in glomeruli (abst) 425
levels during saline volume expansion (abst) 406
release in calves with artificial heart (abst) 389
sodium intake (abst) 384
synthetic, control of GFR (abst) 393
mechanism of natriuretic (abst) 383
Atriopeptin III
atrial extract in rat (abst) 401
influence on rabbit aortic smooth muscle, cGMP (abst). . 1254
in primate (abst) 392
kinetics (abst) 340
Atriopeptins, glomerular effects (abst) 379
Australia, aluminum, bone disease in S-65
Autoantibodies
membranous lupus crossreact with nucleic acid antigen
(abst) 288
to tubular antigens, gold nephropathy 539
lupus SLE (abst) 283
Autoantibody, Goodpasture Syndrome(abst) 287
Autoflorescence
diagnosis of acute tubular necrosis (abst) 289
Autoimmunity
DNA (abst) 268
murine, Ia (abst) 289
Autosomal dominant polycystic
kidney disease, cyst infection in (abst) 203
kidney disease 315
AVP
increased urinary excretion of PGE2 during
antidiuresis 1110
Subject Index: Vol. 29 xli
Axotemia, trends after HD (abst) 224
Azathioprine
CyA, rheumatoid arthritis 1180
in renal transplantation (abst) 435
measure 6TU (abst) 437
Aziocillin's kinetics (abst) 208
Azotemia
rats, B6 deficiency (abst) 228
trends after HD (abst) 224
a2-adrenoceptor, PGE2, cAMP levels 703
B cell hyperactivity in IgA
B cell in aTBM (abst)
Bacterial microcolonies
in peritonitis associated with CAPD (abst) 230
Bartter syndrome
diluting segment function abnormal (abst)
enalapril (abst)
tests of renal diluting ability determine cause (abst).
Basement membrane




cotran sport of NaHCO3 (abst) 362
Na-HCO3 cotransport (abst) 367
membranes, IGF I (abst) 354
Bence Jones Protein, toxicity (abst) 309
Berger's Disease (abst) 191
Beta blockade, ISA alters (abst) 257
Beta 2 microglobulin, ADPKD (abst) 315
Bicarbonate
amiloride effect on permeability (abst) 375
buffered, solution for parenteral use (abst) 369
diuresis, PCO2 (abst) 373
PK of at high, low concentrations (abst) 377
reabsorption across distal tubule 365
regulation of glutamine metabolism in dog kidney 68
renal acid-base metabolism after ischemia 989
binding sites, All (abst) 254
Binding, glomerular, BSA (abst) 265
Biophosphonate, APD, parathyroid (abst) 941
Biopsy
adolescents with renal disease (abst)
fine needle aspiration, transplanted kidney (abst).
renal allograft, value in cyclosporine era (abst)
renal and fine-needle aspiration in transplantation
(abst)
renal in elderly (abst)
65 teenagers with primary nephrotic syndrome (abst)
Blocking agents
Ca+ + activated K+ channels in MTAL (abst) 396
Blood
flow measurement, noninvasive Doppler method (abst). 379
flow, temporal and spatial analysis (abst) 380
red cells, sodium transport in, dialyzed uremics 1197
transfusion, HLA-A, B compatible in transplantation
(abst) 612
Blood pressure
after radical operation in secondary hypertension (abst) ..247
altered by maternal dietary calcium in dogs (abst) 254
captopril on renal hemodynamics (abst) 382
cardiovascular response to hemofiltration 901
Ca2+ in hypertensive (abst) 262
determinants of in renal transplantation (abst) 436
Bone
accumulation of aluminum, osteomalacia S- 17
AL intoxicated rats, increased l,25(OH)2D3 receptors
416 (abst) 165
190 aluminum metabolism S-8
190 Aluminum, longitudinal study (abst) 218
aluminum, PTH and vitamin D3 affect (abst) 213
aluminum, transferrin-dependent, suppression of DNA
(abst) 157
aplastic disease, AL toxicity (abst) 164
biopsy and Al storage (abst) 173
biopsy, aluminum and bone disease in Australia S-65
changes in histology after desferrioxamine treatment. S- 108
children, renal disease in dialyzed (abst) 236
density in hypertension 205
development, Al on mineralization during
matrix-induced 1038
diagnosis of aluminum disease S-96
disease, aluminum-related S-80
disease, experimental aluminum-induced S-32
disease, PTH in aluminum S-87
effects of dietary calcium and sodium on (abst) 173
formation, aluminum influence S-32
formation, calcium efflux (abst) 156
fracturing disease, dialysis encephalopathy S-53
increased receptors in AL intoxicated rats (abst) 165
ion microprobe determination of surface elements
(abst) 164
marrow transplant, cytomegalovirus glomerulopathy... 725
Newcastle disease, aluminum-induced osteodystrophy. S-58
protective effect of verapamil on resorption (abst) 156
scan, 99mTc-methylene diphosphonate in osteodystro-
phy 1058
unresponsiveness of, to PTH in Al-related osteodystro-
612 phy S-49
204 l,25(OH)2D3 and PTH maintain activity of cells (abst) . 164
284 Bone marrow transplantation
renal vasodilation and hyperfiltration (abst) 206
Bovine hemoglobin, renal function (abst) 301
Bowel infarction in dialysis (abst) 212
Bowman's capsule
crescents in CGn (abst) 266
Bradkyinin
cortical interstitial cells (abst) 347
kallidin metylsbradykinin 121
kallikrein 953
lipid peroxidation (abst) 333
quin 2 flourescence in papillary collecting tubule (abst). 344
radioimmunoassay using monoclonal antibodies (abst).. 342
Brain buffering, K depletion (abst) 362
Brain infarcts, K diet reduces (abst) 250
Bright's disease 779
effects of Ca are prevented by magnesium (abst) 263
elevated and rapid loss of renal function in NIDDM
(abst) 182
glomerular injury to preglomerular resistance, hyper-
tension 849
house officers during on call (abst) 253
lead exposure, calcium intake (abst) 198
NaC1 effect in rat (abst) 255
normotensive members of hypertensive families 882
pregnancy, renin angiotensin aldosterone system (abst). 777
reduced, acute renal dysfunction in hypertension (abst) .. 256
renal function in kidney donors 1072
renal function preservation due to reduction (abst) . . . . 320
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Bronchopneumonia, IgA 557
Brush border membrane
age related changes in water, solute permeability (abst) . . 414
basolateral, fluidity differences in (abst) 403
carbonic anhydrase in S3 segment (abst) 370
cortical, effects of aging on (abst) 360
heterogeneity of fractions isolated by centrifugation
(abst) 361
Na+/H+ antiporter with exchanger (abst) 367
permeabilities and fluidity of in cortex (abst) 412
phorbol esters stimulate Na+/H+ (abst) 408
phospholipids induced by mercuric chloride 496
proteins, phosphatidylcholine transfer (abst) 174
transport of H+/OH- (abst) 378
vesicles, cimetidine uptake (abst) 420
Brush border membrane vesicle
Cl/OH exchange coupled by electrical potential (abst).. 370
electrolyte gradients in, 3 techniques (abst) 402
fraction from human renal cortex (abst) 352
kinetic studies of Na+-H+ (abst) 370
phosphate uptake (abst) 155
presteady state kinetics of Na+-H+ exchange (abst)... 374
proximal convoluted tubules (abst) 352
c-sis mRNA in renal tissue (abst) 272
Calcification, vascular in HD (abst) 213
Calcitonin metabolism (abst) 359
Calcitriol
effects of diuretics (abst) 160
hyperparathyroidism (abst) 199
relationship between urinary calcium and calcium in-
take 578
vitamin D3 (abst) 1255
Calcium
absorption in spontaneously hypertensive rat (abst).... 159
activated K+ channels in MTAL (abst) 396
alters blood pressure in dogs (abst) 254
and cyclic AMP messenger function 90
antagonists in hypertension (abst) 241
antagonists on vasoconstrictor prostacyclin (abst) 260
arginine vasopressin action in CCT (abst) 415
augments glomerular capillary hypertension, injury
(abst) 244
a2 and b2 adrenoceptors and free intracellular (abst) . . 1258
carbonate responsible for acid-induced release (abst). . . 156
carbonate, aluminum free agent for control in uremia. S- 114
Ca2+ efflux rate constant in isolated SHR enterocytes
(abst) 252
Ca2+, body composition changes in SHR (abst) 248
channel blockade, antihypertensive efficacy of (abst). . . 257
channel blocker following ischemia (abst) 433
compensatory renal growth by Ca PTH, 1 ,25(OH)2D3. 1124
cortical mitochondria transport (abst) 315
creatinine, renal net acid excretion 743
cyclooxygenase products modulate renal function
(abst) 336
cytosolic Ca2+, fura 2, quin 2 measurement (abst) . . . . 399
dietary effect in hypertension 166
dietary supplementation in hypertension (abst) 241
dietary, genetic variability in response to (abst) 247
effect of Al on parathyroid tissue incubation medium . . 924
effect on BP and Na, K-ATPase in SHR (abst) 262
effiux (abst) 156
gentamicin induces abnormalities (abst) 298
hypercalcemia, role of loop segment in urinary concen-
trating 977
hyperpolarization of proximal tubule cells (abst) 393
impaired vasopressin, cAMP formation by increased
(abst) 425
increased intestinal transport in hypertensive rat (abst) . 244
influx and H2o distribution in aorta, hypertensive
(abst) 243
inositol triphosphate-sensitive pool (abst) 157
inositol 1,4,5-triphosphate releases 695
insulin, reactivity in diabetic (abst) 315
intracellular free, circulating plasma factor (abst) 250
ionized modulates renal function (abst) 381
kinetics, angiotensin II (abst) 424
lead exposure and blood pressure (abst) 198
measurement by FURA-2 (abst) 335
mobilization of vasopressin receptors (abst) 415
mobilizing hormones on brush border and sytoskeleton
(abst) 160
modulation by verapamil of hormonal action 863
mucosal removal on a leaky epithelium (abst) 422
Na+, pressor response to norepinephrine (abst) 261
nephron segment and, determinants of anoxic cell
death 1172
net acid excretion determines fasting urinary calcium . . 743
overload in ischemic renal injury (abst) 300
oxygen free radical injury (abst) 305
phosphate precipitation, aluminum S-20
phospholipid dependent protein kinase (abst) 355
PTH activated, conductive pathway in brush border
(abst) 166
PTH stimulates cellular absorption of (abst) 159
renal channel abnormality in hypertensive rat (abst) . . . 259
sequential changes, PTH secretion and UcAMP excre-
tion (abst) 172
sequestration in LLC-PK1 cells (abst) 302
stone former, hydrochlorothiazide (abst) 775
stone formers, soft vs. hard water (abst) 778
stress, hypertension in SHR (abst) 247
toxicity to renal medulla (abst) 298
urinary and intake relationship during calcitriol therapy .. 578
urinary, oxalate crystal growth inhibitor 829
urine excretion post renal mass reduction (abst) 321
Calcium oxalate, uremic serum (abst) 315
Calelectrin in renal tissue (abst) 291
cAMP
acidosis inhibits HCO3 secretion in turtle (abst) 362
mediates PTH stimulation of 25-OH-vitamin D3 activ-
ity (abst) 162
process for K groups in glomerular polyanion complex
(abst) 285
protein kinase and Na+/H+ exchange (abst) 378
regulation of levels by PGE2 and a2 adrenoceptors . . . . 703
system, All, AVP, Bradykinin, Meclofenamate on PG
and (abst) 341
system,beta-adrenoceptors coupled to (abst) 335
Campylobacter pericarditis (abst) 228
Cancer
renal, inhibitory effect of I a,25-dihydroxyvitamin D3... 834
Cancer chemotherapy
acute hyponatremia during forced diuresis (abst) 191
CAPD
air under diaphragm significance (abst) 233
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